[1]
|
Nelson, N.J. (2010) Circulating Tumor Cells: Will They Be Clinically Useful? JNCI: Journal of the National Cancer Institute, 102, 146-148. https://doi.org/10.1093/jnci/djq016
|
[2]
|
Vasseur, A., Kiavue, N., Bidard, F.C., et al. (2021) Clinical Utility of Circulating Tumor Cells: An Update. Molecular Oncology, 15, 1647-1666. https://doi.org/10.1002/1878-0261.12869
|
[3]
|
Huang, L., Yang, Y., Yang, F., et al. (2018) Functions of EpCAM in Physiological Processes and Diseases (Review). International Journal of Molecular Medicine, 42, 1771-1785. https://doi.org/10.3892/ijmm.2018.3764
|
[4]
|
Maetzel, D., Denzel, S., Mack, B., et al. (2009) Nuclear Signalling by Tumour-Associated Antigen EpCAM. Nature Cell Biology, 11, 162-171. https://doi.org/10.1038/ncb1824
|
[5]
|
Gorges, T.M., Tinhofer, I., Drosch, M., et al. (2012) Circulating Tumour Cells Escape from EpCAM-Based Detection Due to Epithelial-to-Mesenchymal Transition. BMC Cancer, 12, Article No. 178.
https://doi.org/10.1186/1471-2407-12-178
|
[6]
|
Yokobori, T., Iinuma, H., Shimamura, T., et al. (2013) Plastin3 Is a Novel Marker for Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition and Is Associated with Colorectal Cancer Prognosis. Cancer Research, 73, 2059-2069. https://doi.org/10.1158/0008-5472.CAN-12-0326
|
[7]
|
Sugimachi, K., Yokobori, T., Iinuma, H., et al. (2014) Aberrant Expression of Plastin-3 via Copy Number Gain Induces the Epithelial-Mesenchymal Transition in Circulating Colorectal Cancer Cells. Annals of Surgical Oncology, 21, 3680-3690. https://doi.org/10.1245/s10434-013-3366-y
|
[8]
|
Armstrong, A.J., Marengo, M.S., Oltean, S., et al. (2011) Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers. Molecular Cancer Research, 9, 997-1007.
https://doi.org/10.1158/1541-7786.MCR-10-0490
|
[9]
|
Ning, Y., Hanna, D.L., Zhang, W., et al. (2015) Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Molecular Cancer Therapeutics, 14, 2401-2408. https://doi.org/10.1158/1535-7163.MCT-15-0359
|
[10]
|
Zhao, R., Cai, Z., Li, S., et al. (2017) Expression and Clinical Relevance of Epithelial and Mesenchymal Markers in Circulating Tumor Cells from Colorectal Cancer. Oncotarget, 8, 9293-9302. https://doi.org/10.18632/oncotarget.14065
|
[11]
|
Matsusaka, S., Suenaga, M., Mishima, Y., et al. (2011) Circulating Tumor Cells as a Surrogate Marker for Determining Response to Chemotherapy in Japanese Patients with Metastatic Colorectal Cancer. Cancer Science, 102, 1188-1192.
https://doi.org/10.1111/j.1349-7006.2011.01926.x
|
[12]
|
Aggarwal, C., Meropol, N.J., Punt, C.J., et al. (2013) Relationship among Circulating Tumor Cells, CEA and Overall Survival in Patients with Metastatic Colorectal Cancer. Annals of Oncology, 24, 420-428.
https://doi.org/10.1093/annonc/mds336
|
[13]
|
Sastre, J., Vidaurreta, M., Gómez, A., et al. (2013) Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients with Metastatic Colorectal Cancer Treated with Chemotherapy Plus Bevacizumab. Clinical Colorectal Cancer, 12, 280-286. https://doi.org/10.1016/j.clcc.2013.06.001
|
[14]
|
van Dalum, G., Stam, G.J., Scholten, L.F., et al. (2015) Importance of Circulating Tumor Cells in Newly Diagnosed Colorectal Cancer. International Journal of Oncology, 46, 1361-1368. https://doi.org/10.3892/ijo.2015.2824
|
[15]
|
Coumans, F.A., Ligthart, S.T., Uhr, J.W., et al. (2012) Challenges in the Enumeration and Phenotyping of CTC. Clinical Cancer Research, 18, 5711-5718. https://doi.org/10.1158/1078-0432.CCR-12-1585
|
[16]
|
Tsai, W.S., Chen, J.S., Shao, H.J., et al. (2016) Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients. Scientific Reports, 6, Article No. 24517. https://doi.org/10.1038/srep24517
|
[17]
|
Krebs, M.G., Renehan, A.G., Backen, A., et al. (2015) Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 14, 115-122.
|
[18]
|
Aranda, E., Viéitez, J.M., Gómez-España, A., et al. (2020) FOLFOXIRI Plus Bevacizumab versus FOLFOX Plus Bevacizumab for Patients with Metastatic Colorectal Cancer and ≥3 Circulating Tumour Cells: The Randomised Phase III VISNÚ-1 Trial. ESMO Open, 5, e944.
|
[19]
|
Fan, T., Zhao, Q., Chen, J.J., et al. (2009) Clinical Significance of Circulating Tumor Cells Detected by an Invasion assay in Peripheral Blood of Patients with Ovarian Cancer. Gynecologic Oncology, 112, 185-191.
|
[20]
|
Galizia, G., Gemei, M., Orditura, M., et al. (2013) Postoperative Detection of Circulating Tumor Cells Predicts Tumor Recurrence in Colorectal Cancer Patients. Journal of Gastrointestinal Surgery, 17, 1809-1818.
https://doi.org/10.1007/s11605-013-2258-6
|
[21]
|
Mamdouhi, T., Twomey, J.D., McSweeney, K.M., et al. (2019) Fugitives on the Run: Circulating Tumor Cells (CTCs) in Metastatic Diseases. Cancer and Metastasis Reviews, 38, 297-305. https://doi.org/10.1007/s10555-019-09795-4
|
[22]
|
Marcuello, M., Vymetalkova, V., Neves, R., et al. (2019) Circulating Biomarkers for Early Detection and Clinical Management of Colorectal Cancer. Molecular Aspects of Medicine, 69, 107-122.
https://doi.org/10.1016/j.mam.2019.06.002
|